Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DNA NASDAQ:PGEN NASDAQ:SPRO NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$12.18-7.3%$10.05$5.00▼$16.85$769.11M1.51.59 million shs1.36 million shsPGENPrecigen$1.67-2.3%$1.57$0.65▼$2.17$504.76M1.783.00 million shs2.02 million shsSPROSpero Therapeutics$2.30-0.9%$2.59$0.51▼$3.22$129.71M1.39770,756 shs518,730 shsTYRATyra Biosciences$10.37-5.1%$10.10$6.42▼$29.60$580.27M1.08226,927 shs283,932 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks-7.04%-12.72%-3.87%+73.01%-19.87%PGENPrecigen-2.34%+6.37%+3.73%+6.37%+9.87%SPROSpero Therapeutics-0.86%-1.29%-20.69%+255.49%+63.12%TYRATyra Biosciences-5.12%-6.24%+3.18%-4.51%-53.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNAGinkgo Bioworks1.1775 of 5 stars1.03.00.00.01.92.51.3PGENPrecigen3.9979 of 5 stars3.51.00.04.73.11.70.6SPROSpero Therapeutics3.7349 of 5 stars3.35.00.04.70.00.00.6TYRATyra Biosciences1.6645 of 5 stars3.50.00.00.01.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNAGinkgo Bioworks 2.00Hold$8.50-30.21% DownsidePGENPrecigen 3.00Buy$6.00259.28% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00117.39% UpsideTYRATyra Biosciences 3.00Buy$30.83197.33% UpsideCurrent Analyst Ratings BreakdownLatest SPRO, DNA, TYRA, and PGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.005/21/2025TYRATyra BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$33.005/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNAGinkgo Bioworks$227.04M3.14N/AN/A$13.17 per share0.92PGENPrecigen$4.20M117.34N/AN/A$0.13 per share12.85SPROSpero Therapeutics$47.98M2.68N/AN/A$0.85 per share2.71TYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)PGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)TYRATyra Biosciences-$86.48M-$1.63N/AN/AN/AN/A-26.90%-25.54%8/6/2025 (Estimated)Latest SPRO, DNA, TYRA, and PGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DNAGinkgo Bioworks-$1.44N/AN/AN/A$41.60 millionN/A8/13/2025Q2 2025PGENPrecigen-$0.14N/AN/AN/A$0.67 millionN/A8/6/2025Q2 2025TYRATyra Biosciences-$0.53N/AN/AN/AN/AN/A8/4/2025Q2 2025SPROSpero Therapeutics-$0.35N/AN/AN/AN/AN/A5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/13/2025Q1 2025SPROSpero Therapeutics-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 million5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNAGinkgo BioworksN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNAGinkgo BioworksN/A4.884.88PGENPrecigenN/A3.533.53SPROSpero TherapeuticsN/A2.562.56TYRATyra BiosciencesN/A22.7822.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNAGinkgo Bioworks78.63%PGENPrecigen33.51%SPROSpero Therapeutics25.60%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipDNAGinkgo Bioworks9.72%PGENPrecigen47.10%SPROSpero Therapeutics5.50%TYRATyra Biosciences15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionablePGENPrecigen190295.18 million156.15 millionOptionableSPROSpero Therapeutics15055.91 million52.84 millionOptionableTYRATyra Biosciences2053.09 million45.02 millionOptionableSPRO, DNA, TYRA, and PGEN HeadlinesRecent News About These CompaniesTyra Biosciences (TYRA) to Release Quarterly Earnings on WednesdayJuly 31 at 6:14 AM | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.83 Consensus Target Price from BrokeragesJuly 29, 2025 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Buy" by BrokeragesJuly 26, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Trading Down 3% - Here's WhyJuly 23, 2025 | marketbeat.comTyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call SeriesJuly 21, 2025 | prnewswire.comTyra Biosciences (NASDAQ:TYRA) Trading Up 5.7% - Should You Buy?July 16, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.9% - What's Next?July 15, 2025 | marketbeat.comTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - MorningstarJuly 9, 2025 | morningstar.comMTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025July 8, 2025 | prnewswire.comTyra Biosciences (NASDAQ:TYRA) Shares Down 3.3% - What's Next?July 3, 2025 | marketbeat.comTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deTYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBCJuly 2, 2025 | targetedonc.comTTyra Biosciences begins patient dosing in phase 2 study of TYRA-300 in low-grade intermediate risk non-muscle invasive bladder cancerJuly 1, 2025 | pharmabiz.comPTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)June 30, 2025 | prnewswire.comInsider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 9,568 Shares of StockJune 21, 2025 | insidertrades.comTyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in StockJune 17, 2025 | insidertrades.comTyra Biosciences to Participate at Upcoming Investor ConferencesMay 12, 2025 | prnewswire.comOne Tyra Biosciences Insider Raised Stake By 284% In Previous YearMay 9, 2025 | finance.yahoo.comTyra Biosciences Reports First Quarter 2025 Financial Results and HighlightsMay 8, 2025 | prnewswire.comWhy Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%May 6, 2025 | aaii.comATyra Biosciences price target lowered to $28 from $29 at BofAMarch 30, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerSmart Investors Are Watching These 3 Undervalued StocksBy Gabriel Osorio-Mazilli | July 12, 2025View Smart Investors Are Watching These 3 Undervalued StocksA Huge Bet on Uranium: Why Traders Are Piling Into the URNM ETFBy Jeffrey Neal Johnson | July 24, 2025View A Huge Bet on Uranium: Why Traders Are Piling Into the URNM ETFSPRO, DNA, TYRA, and PGEN Company DescriptionsGinkgo Bioworks NYSE:DNA$12.18 -0.96 (-7.31%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$12.17 -0.01 (-0.08%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Precigen NASDAQ:PGEN$1.67 -0.04 (-2.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.72 +0.05 (+2.93%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Spero Therapeutics NASDAQ:SPRO$2.30 -0.02 (-0.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.31 +0.01 (+0.61%) As of 08/1/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Tyra Biosciences NASDAQ:TYRA$10.37 -0.56 (-5.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.37 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
